RecruitingNCT07495865

Post-market Clinical Follow-up (PMCF) Study of Safety and Performance of 502-01 AnGelHA 2

A Prospective, Open-label, Non-interventional Post-market Study Evaluating the Performance and Safety of AnGelHA 2 Filler for Correcting Moderate to Severe Wrinkles and Folds and Facial Contour Remodeling in Routine Clinical Use.

Sponsor

Glyance

Enrollment

87 participants

Start Date

Feb 8, 2026

Study Type

OBSERVATIONAL

Conditions

Wrinkles

Summary

Post-market clinical follow-up (PMCF) investigation to evaluate the performance and safety of AnGelHA 2 filler for the correction of moderate to severe wrinkles and folds and facial contour remodeling, in a routine clinical setting.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with wrinkles. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(1)

Glyance Ltd

Lod, Israel, Israel

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07495865

Related Trials

Effect of Single Facial Acupuncture on Dermal Structure and Appearance Satisfaction

NCT076642801 location

Safety and Efficacy Evaluation of High Intensity Focused Ultrasound Device in Eyebrow Lifting

NCT067245103 locations